SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-23-001787
Filing Date
2023-08-11
Accepted
2023-08-11 17:00:48
Documents
57
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q scps-20230630x10q.htm   iXBRL 10-Q 1032464
2 EX-31.1 scps-20230630xex31d1.htm EX-31.1 12932
3 EX-31.2 scps-20230630xex31d2.htm EX-31.2 12961
4 EX-32.1 scps-20230630xex32d1.htm EX-32.1 6243
5 EX-32.2 scps-20230630xex32d2.htm EX-32.2 6304
  Complete submission text file 0001410578-23-001787.txt   4329985

Data Files

Seq Description Document Type Size
6 EX-101.SCH scps-20230630.xsd EX-101.SCH 44781
7 EX-101.CAL scps-20230630_cal.xml EX-101.CAL 24347
8 EX-101.DEF scps-20230630_def.xml EX-101.DEF 138800
9 EX-101.LAB scps-20230630_lab.xml EX-101.LAB 337978
10 EX-101.PRE scps-20230630_pre.xml EX-101.PRE 251557
51 EXTRACTED XBRL INSTANCE DOCUMENT scps-20230630x10q_htm.xml XML 522477
Mailing Address 420 LEXINGTON AVENUE, SUITE 300 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE, SUITE 300 NEW YORK NY 10170 (212) 479-2513
Scopus BioPharma Inc. (Filer) CIK: 0001772028 (see all company filings)

IRS No.: 821248020 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39788 | Film No.: 231165033
SIC: 2834 Pharmaceutical Preparations